Nephrology · KIMS Secunderabad
Sickle Cell Nephropathy — Protecting Kidney Function in Sickle Cell Disease
Sickle cell disease (SCD) — caused by homozygous HbS mutation (HbSS) or compound heterozygosity (HbSC, HbS-beta thalassaemia) — affects the kidneys through multiple mechanisms, collectively termed sickle cell nephropathy. Kidney disease is one of the most significant long-term complications of SCD, affecting an estimated 30% of patients with SCD over their lifetime and contributing substantially to morbidity and early mortality. In India, SCD is concentrated in specific regions and communities — tribal populations of Central India (Chhattisgarh, Odisha, Madhya Pradesh, Maharashtra) and parts of Andhra Pradesh and Telangana. KIMS Secunderabad, serving the Telangana and Andhra Pradesh population, encounters sickle cell nephropathy in a clinically significant proportion of its nephrology patients.
The kidneys are particularly vulnerable to sickling because the renal medulla — the inner zone of the kidney — has conditions that actively promote HbS polymerisation: low oxygen tension, low pH, high osmolality, and slow blood flow through the vasa recta capillaries. These conditions cause red blood cells containing HbS to sickle within the medullary vessels, causing medullary ischaemia, infarction, and a cascade of structural and functional abnormalities that evolve over years to decades.
The spectrum of kidney involvement in sickle cell disease
Hyposthenuria — impaired urine concentrating ability
The earliest and most universal kidney manifestation of SCD — occurring in early childhood and present in virtually all patients with SCD. Sickling in the vasa recta destroys the countercurrent multiplication mechanism in the renal medulla, eliminating the kidney's ability to produce concentrated urine. The result: obligatory hyposthenuric (dilute) urine at a fixed osmolality of approximately 300 to 350 mOsm/kg. Clinically, this causes polyuria and polydipsia (the patient must drink large volumes to compensate for the obligatory water loss) and increased susceptibility to dehydration — which itself worsens sickling and triggers crises.
Haematuria — medullary ischaemia and papillary necrosis
Painless gross haematuria is common in SCD — occurring in 3 to 4% of HbSS patients and even more commonly in HbSC patients (interestingly, the less severe sickling disorder causes more renal haematuria, possibly because HbSC red cells are more viscous in the hypertonic medullary environment). The mechanism: sickling in the medullary capillaries causes microinfarction, rupture of small vessels, and sloughing of papillary tissue (papillary necrosis). Haematuria in SCD patients must be taken seriously — while often self-limiting, it can be massive and require intervention, and the possibility of a concurrent bladder or upper tract tumour must always be excluded.
Proteinuria and glomerular hyperfiltration
Glomerular hyperfiltration — an increased GFR from enlarged glomeruli and high renal blood flow — is universal in young patients with SCD. The enlarged glomeruli and the chronic anaemia-driven high cardiac output maintain an abnormally high filtration rate. While initially protective (maintaining kidney function despite ongoing medullary injury), this hyperfiltration eventually damages the glomerular filtration barrier, causing proteinuria. Microalbuminuria (ACR 3 to 30 mg/mmol) develops in 20 to 30% of SCD patients — the first marker of glomerular injury that predicts progression to overt proteinuria and CKD.
Chronic kidney disease — progressive and multifactorial
CKD develops in approximately 20 to 30% of patients with SCD and is the most significant long-term kidney complication. The mechanisms are multiple and additive: vascular injury from repeated sickling in medullary and glomerular vessels, iron overload nephropathy (from transfusion therapy), direct haemoglobin tubular toxicity (from intravascular haemolysis), FSGS-pattern glomerulosclerosis (from years of hyperfiltration), and acute kidney injury from sickle crises (each crisis potentially leaving residual nephron loss). CKD in SCD progresses to ESRD in 4 to 18% of patients — a serious complication associated with high mortality.
Acute kidney injury in sickle crisis
Acute sickle crises can cause AKI through ischaemic tubular injury (from massive medullary sickling) and haemoglobin-mediated tubular toxicity (from intravascular haemolysis during a crisis). The AKI is usually intrinsic (acute tubular necrosis) and partly reversible with hydration, avoidance of nephrotoxins, and treatment of the underlying crisis. CRRT is available at KIMS for severe crisis-related AKI.
Monitoring at KIMS — what to check and how often
Urine ACR (albumin-to-creatinine ratio)
Frequency: annually from age 10 in HbSS. Detects microalbuminuria — the earliest reversible marker of glomerular injury and the window for ACE inhibitor initiation.
Serum creatinine and eGFR
Frequency: annually from age 10. Tracks CKD progression. A falling eGFR — even within the "normal" range — is clinically significant in a young SCD patient with previously high baseline GFR from hyperfiltration.
Urine dipstick
Frequency: at each clinic visit. Detects haematuria and proteinuria at the bedside — a simple low-cost first check that prompts further quantification with ACR or 24-hour urine when positive.
Blood pressure
Frequency: at every visit. Hypertension is a modifiable risk factor for CKD progression in SCD — target below 130/80 mmHg.
Renal ultrasound
Frequency: every 1–2 years. Detects papillary necrosis, medullary echogenicity changes, and hydronephrosis. Also important for excluding medullary renal carcinoma in any HbAS patient with haematuria.
24-hour urine protein
Performed when ACR is elevated — to quantify proteinuria precisely for treatment decisions. Quantitative protein measurement guides ACE inhibitor titration and the decision to escalate therapy.
Treatment — kidney protection in SCD
ACE inhibitors or ARBs — at microalbuminuria
Initiated at microalbuminuria (ACR above 3 mg/mmol) in patients with SCD. Reduce intraglomerular pressure and proteinuria, slowing CKD progression. The most important kidney-protective intervention in SCD nephropathy.
Hydroxyurea (hydroxycarbamide)
The cornerstone of SCD disease-modifying therapy. Increases HbF production, reducing HbS polymerisation and sickling. In addition to reducing pain crises and acute chest syndrome, hydroxyurea has been shown to reduce albuminuria and slow eGFR decline in SCD patients. Started at KIMS in all eligible patients with HbSS.
Blood pressure control
Target below 130/80 mmHg. Hypertension in SCD accelerates CKD progression — even modest blood pressure elevations in young SCD patients warrant treatment given the long-horizon trajectory toward CKD.
Avoidance of dehydration
Sickle cell patients must maintain adequate hydration at all times. Dehydration raises medullary osmolality, promotes sickling, and worsens medullary ischaemia. Education about fluid intake targets — minimum 2 to 2.5 litres daily, more during hot weather and exercise.
Avoidance of nephrotoxins
NSAIDs (which reduce medullary blood flow via prostaglandin inhibition, already compromised in SCD), IV contrast (increased risk of contrast nephropathy in SCD), and aminoglycosides are avoided where possible. When iodinated contrast cannot be avoided, pre-procedure hydration and a nephrology review reduce the risk.
Transfusion programme management
Regular transfusions reduce HbS percentage but cause iron overload. Iron chelation therapy prevents iron overload nephropathy — a recognised contributor to CKD in chronically transfused SCD patients.
Kidney transplant
For SCD patients reaching ESRD. Transplant outcomes in SCD are modestly worse than in the general ESRD population, partly from continued systemic sickling affecting the transplanted kidney's vasculature. Hydroxyurea and chronic transfusion programme maintenance post-transplant aim to reduce HbS. KIMS evaluates SCD patients for kidney transplant with careful assessment of cardiac and pulmonary SCD complications that affect transplant fitness.
Book a Sickle Cell Nephropathy Assessment at KIMS
Frequently Asked Questions — Sickle Cell Nephropathy
Some degree of kidney involvement — particularly hyposthenuria (inability to concentrate urine) and medullary changes — occurs in virtually all patients with HbSS disease from early childhood. Clinically significant kidney disease (proteinuria, declining eGFR, CKD) develops in approximately 20 to 30% of HbSS patients over their lifetime, and ESRD occurs in 4 to 18%. The risk varies with genotype — HbSS is more severe than HbSC and HbS-beta thalassaemia. Early and regular monitoring (annual urine ACR and eGFR from age 10) identifies kidney disease while it is still modifiable with ACE inhibitors and hydroxyurea.
Haematuria in sickle cell disease is most commonly from medullary microinfarction and papillary necrosis — the sickling of red blood cells in the renal medullary capillaries (vasa recta) causes ischaemia, rupture of small medullary vessels, and sloughing of papillary tissue, releasing blood into the collecting system. This haematuria is usually painless and may be gross (visibly red urine) or microscopic. Interestingly, HbSC disease (the compound heterozygous form, generally less severe than HbSS) causes renal haematuria more frequently than HbSS — possibly because HbSC red cells are more viscous in the hyperosmolar medullary environment.
Early intervention significantly reduces the risk of progression to significant CKD. The most important preventive measures: hydroxyurea (started early — clinical trials show it reduces albuminuria and slows eGFR decline in HbSS patients), ACE inhibitors or ARBs started at the microalbuminuria stage, blood pressure control, maintenance of hydration, and avoidance of nephrotoxins. Annual kidney function monitoring (urine ACR and eGFR) from age 10 identifies the window for intervention before irreversible damage accumulates.
Yes — hydroxyurea is kidney-protective in sickle cell nephropathy, not nephrotoxic. Hydroxyurea works by stimulating fetal haemoglobin (HbF) production, which reduces HbS polymerisation and sickling. Clinical studies show that hydroxyurea reduces albuminuria and slows eGFR decline in SCD patients. It does not cause direct kidney toxicity at the doses used for SCD. Hydroxyurea can cause leucopenia and thrombocytopenia — requiring monitoring of full blood count — but this is managed by dose adjustment rather than cessation.
Yes — kidney transplant is the treatment for SCD-related ESRD and provides better outcomes than long-term dialysis. Outcomes are somewhat less favourable than in the general ESRD population — SCD continues to affect the transplanted kidney's vasculature, and sickle crises can occur post-transplant. Post-transplant management at KIMS includes continuation of hydroxyurea, careful haematological monitoring, and avoidance of dehydration and other sickling triggers. Living donor transplant (from a donor without SCD or sickle trait) is preferred where available.
Mild to moderate haematuria from sickle cell medullary ischaemia is managed conservatively: vigorous oral and IV hydration (to reduce medullary tonicity and improve blood flow), rest, and avoidance of nephrotoxins and diuretics. Alkalization of urine (oral sodium bicarbonate or IV sodium bicarbonate) reduces sickling by raising medullary pH. Epsilon-aminocaproic acid (tranexamic acid) — an antifibrinolytic — can be used for persistent severe haematuria that does not respond to conservative management. Massive haematuria requiring intervention is managed by interventional radiology (selective embolisation of the bleeding medullary artery) — a nephron-sparing approach preferred over nephrectomy.
Sickle trait (one copy of HbS — HbAS) is generally considered benign. However, a small number of HbAS individuals develop medullary renal carcinoma — a rare but aggressive kidney cancer specifically associated with sickle trait. Any HbAS individual with unexplained haematuria or a renal mass should be evaluated for medullary renal carcinoma. HbAS is also associated with a modestly increased risk of haematuria from medullary sickling (similar mechanism to HbSS but much less severe) and a slight increase in ESRD risk — though far less than HbSS.
KIMS Secunderabad — Dr. V. S. Reddy (Senior Consultant Nephrologist, transplant programme), ACE inhibitor and hydroxyurea protocol for early nephropathy, annual urine ACR and eGFR monitoring programme, CRRT for crisis-related AKI, kidney transplant programme for ESRD including living donor evaluation. NABH and NABL accredited. Call 040-4488-5000.